Delcath Systems to Present at Access to Giving Virtual Conference on July 13, 2021 at 3 p.m. ET

Rhea-AI Summary

Delcath Systems, focused on interventional oncology for liver cancers, will present at the Access to Giving Virtual Conference on July 13, 2021, at 3 p.m. ET. CEO Gerard Michel will lead the discussion. This conference allows companies to engage with investors while supporting charitable causes. Registration is free and can be done online. Delcath’s investigational product, HEPZATO KIT, aims to deliver high-dose chemotherapy to the liver, although it is not approved by the FDA in the U.S. The system is marketed in Europe as Delcath CHEMOSAT.

NEW YORK, July 07, 2021 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of rare primary and metastatic cancers of the liver, announced today that the company will present at Access to Giving Virtual Conference. The presentation will be given by Delcath’s Chief Executive Officer, Gerard Michel. The conference is free to all registrants.

Registration Details
Date: Tuesday, July 13, 2021
Time: 3 p.m. ET
Link: https://access-to-giving.events.issuerdirect.com/signup   

To learn more about the event or to schedule a one-on-one meeting with Delcath’s management, please visit https://www.accesstogiving.com/ or email james@haydenir.com.  

About Access to Giving Virtual Conference

Access to Giving is a first-of-its-kind virtual investor conference where companies will have the opportunity to present their story and conduct 1x1 meetings with qualified investors, for charity. Investors will make donations to purchase a block of meetings to meet with companies.

About Delcath Systems, Inc.

Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. Our investigational product, HEPZATO KIT (melphalan hydrochloride for injection/hepatic delivery system), is designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. HEPZATO KIT has not been approved by the U.S. Food & Drug Administration (FDA) for sale in the U.S. In Europe, our system is marketed under the trade name Delcath CHEMOSAT® Hepatic Delivery System for Melphalan (CHEMOSAT) and has been CE Marked and used at major medical centers to treat a wide range of cancers of the liver. CHEMOSAT is being marketed under an exclusive licensing agreement with medac GmbH, a privately held multi-national pharmaceutical company headquartered in Germany that specializes in the treatment and diagnosis of oncological, urological and autoimmune diseases.

Contact

Delcath Investor Relations
Email: investorrelations@delcath.com

Hayden IR
James Carbonara
(646)-755-7412
james@haydenir.com

FAQ

What is Delcath Systems' presentation at the Access to Giving Virtual Conference about?

Delcath Systems will present its interventional oncology innovations, specifically focusing on treatments for liver cancers.

When is Delcath Systems' presentation at the Access to Giving Virtual Conference scheduled?

The presentation is scheduled for July 13, 2021, at 3 p.m. ET.

Who will present for Delcath Systems at the conference?

Gerard Michel, the Chief Executive Officer of Delcath Systems, will present at the conference.

How can one register for the Access to Giving Virtual Conference?

Registration for the conference is free and can be completed via the provided event link.

What is HEPZATO KIT developed by Delcath Systems?

HEPZATO KIT is an investigational product designed for high-dose chemotherapy delivery to the liver.

Is HEPZATO KIT approved by the FDA in the U.S.?

No, HEPZATO KIT has not been approved by the FDA for sale in the U.S.

In which region is CHEMOSAT marketed, and what does it treat?

CHEMOSAT is marketed in Europe and is used to treat various liver cancers.

What is the purpose of the Access to Giving Virtual Conference?

The conference allows companies to present their stories and engage in one-on-one meetings with investors for charitable fundraising.